Sajith Wickramasekara

Sajith Wickramasekara, co-founder and CEO of Benchling, dives deep into the intersection of AI and biotechnology. He discusses how AI agents can drastically reduce the time and cost of drug development. Sajith addresses the current state of biotech, likening it to a dot-com bust, and highlights China's rapid advancement in the pharma sector. He also shares insights on interdisciplinary collaboration between scientists and technologists, the importance of AI in improving molecule quality, and the necessity for trust in AI systems.